¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"catalytic model"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • catalytic
    Ã˸Å-
  • catalytic power
    Ã˸ŷÂ
  • catalytic reaction
    Ã˸ŹÝÀÀ
  • animal model
    µ¿¹°¸ðÇü
  • atomic model
    ¿øÀÚ¸ðÇü
  • additive model
    µ¡¼À¸ðµ¨
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • compartment model
    ±¸È¹¸ðµ¨
  • compartmentalization model
    ±¸È¹È­¸ðÇü
  • core conductor model
    ÇÙÀüµµÃ¼¸ðÇü
  • demonstration model
    ½Ã¹ü¸ðÇü
  • fluid mosaic model
    À¯µ¿¸ðÀÚÀÌÅ©¸ðµ¨
  • general linear model
    ÀϹݼ±Çü¸ðµ¨
  • gnathostatic model
    ÅθðÇü, ¾ÇŸðÇü
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • model
    ¸ðÇü, ¸ðµ¨
  • animal model
    µ¿¹°¸ðÇü
  • plaster model
    ¼®°í¸ðÇü
  • symmetry model
    ´ëĪÇü, ´ëμ³
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • catalytic
    Ã˸Å-
  • catalytic power
    Ã˸ŷÂ
  • catalytic reaction
    Ã˸ŹÝÀÀ
  • absolute risk model
    Àý´ëÀ§Çè¸ðÇü
  • additive model
    µ¡¼À¸ðµ¨
  • animal model
    µ¿¹°¸ðÇü
  • atomic model
    ¿øÀÚ¸ðÇü
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • compartment model
    ±¸È¹¸ðµ¨
  • compartmentalization model
    ±¸È¹È­¸ðÇü
  • core conductor model
    ÇÙÀüµµÃ¼¸ðÇü
  • demonstration model
    ½Ã¹ü¸ðÇü
  • fluid mosaic model
    À¯µ¿¸ðÀÚÀÌÅ©¸ðµ¨
  • general linear model
    ÀϹݼ±»ó¸ðµ¨
  • gnathostatic model
    ÅθðÇü, ¾ÇŸðÇü
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • ITE =in the ear model
    ±Í¼ÓÇü(º¸Ã»±â)
  • absolute risk model
    Àý´ëÀ§Çè¸ðµ¨
  • gnathostatic model
    ¾ÇŸðÇü(¡­Ù¼úþ).
  • health belief model
    °Ç°­¹ÏÀ½ ¸ðÇü.
  • homeostatic model
    Ç×»ó¼º ¸ðÇü(Ù¼úþ)<Ç¥ÁØÇü>
  • in-the-ear model
    ±Í¼ÓÇü(º¸Ã»±â)
  • plaster model
    ±é½º Çü(¡­úþ), ¼®°í ¸ðÇü.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • catalytic
    Ã˸żº(ÀÇ).
  • catalytic center
    Ã˸ÅÁ߽ɺÎÀ§(õºØÚñéãýÝ»êÈ).
  • catalytic power
    Ã˸ŷÂ.
  • catalytic reaction
    Ã˸ŹÝÀÀ(¡­Úãëë).
  • absolute risk model
    Àý´ëÀ§Çè¸ðµ¨
  • atomic model
    ¿øÀÚ¸ðÇü(¡­Ù¼úþ).
  • biopsychological model
    »ýü½É¸®ÇÐÀû ¸ðµ¨
  • bulk phase model
    µ¢¾î¸® À§»ó ¸ðÇü
  • compartmentalization model
    ±¸È¹È­ ¸ðÇü
  • core conductor model
    ÇÙÀüµµÃ¼¸ðÇü(ú·ï³Óôô÷Ù¼úþ).
  • developmental model
    ¹ß´Þ(Û¡Ó¹)¸ðÇü
  • double helix, DNA model
  • ear model(ITE), in the
    ±Í¼ÓÇü(º¸Ã»±â)
  • fluid mosaic model
    À¯µ¿(×µÔÑ)¸ðÀÚÀÌÅ©¸ðµ¨.
  • fluid mosaic model
    À¯µ¿¼º ¸ðÀÚÀÌÅ© ¸ðµ¨
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • catalytic amount
    Ã˸ŷ®(õºØÚÕá)
  • catalytic antibody
    Ã˸ÅÇ×ü(õºØÚù÷ô÷)
  • catalytic center
    Ã˸ÅÁß½É(õºØÚñéãý)
  • catalytic center activity
    Ã˸ÅÁß½É È°¼º(õºØÚñéãýüÀàõ)
  • catalytic constant
    Ã˸Żó¼ö(õºØÚßÈâ¦)
  • catalytic exchange method
    Ã˸ű³È¯¹ý(õºØÚÎßüµÛö)
  • catalytic rate constant
    Ã˸żӵµ»ó¼ö(õºØÚáÜÓøßÈâ¦)
  • catalytic reduction method
    Ã˸Åȯ¿ø¹ý(õºØÚü½êªÛö)
  • catalytic site
    Ã˸Å(õºØÚ)ÀÚ¸®
  • catalytic subunit
    Ã˸žƴÜÀ§(õºØÚä¬Ó¤êÈ)
  • alternate-site model
    ±³´ëºÎÀ§(ÎßÓÛÝ»êÈ)¸ðÅÚ
  • asymmetric strand transfer model
    ºñ´ëĪ(ÞªÓßöà) °¡´ÚÀüÀÌ(ï®ì¹) ¸ðµ¨
  • ball and stick model
    °ø ¸·´ë ¸ðµ¨
  • Benson model
    º¥¼Õ ¸ðµ¨
  • bilayer model
    À̺ÐÀÚÃþ(ì£ÝÂí­öµ) ¸ðµ¨
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • bulk phase model
    µ¢¾î¸®À§»ó¸ðÇü
  • compartmentalization model
    ±¸È¹È­¸ðÇü
  • general linear model
    ÀϹÝÀû ¼±Çü¸ðµ¨, ÀÏ¹Ý ¼±»ó¸ðµ¨
  • model
    ¸ðÇü, Ç¥ÁØÇü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CPK cell population kinetic [model]; creatine phosphokinase
GHPM general health policy model
GLIM generalized linear interactive model
GLM general linear model
HBM health belief model; hypertonic buffered medium
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
C Catalytic
DNA-PKcs DNA-PK catalytic sub-unit
DNA-PKCS DNA-dependent protein kinase catalytic subunit
hTERT Human telomerase catalytic subunit
MCP Multi-Catalytic Proteinase
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • model spray ¸ðÇü»ó¿¡ Ç¥½ÃÇÑ ¿¬ÇÊ ¼±ÀÌ Áö¿öÁöÁö ¾Ê°Ô Çϱâ À§ÇØ »ç¿ëµÇ´Â Àç·á.

    model trimmer

    ¸ðÇü ´Ùµë±â, ¸ðÇü »èÇÕ±â
    ¸ðÇüÀ» »èÁ¦ÇÏ¿© ÀÏÁ¤ÇÑ ±Ô°ÝÀ¸·Î Á¦ÀÛÇϱâ À§ÇØ »ç¿ëÇÏ´Â ±â±¸.
  • catalytic center
    Ã˸ŠÁ᫐ ºÎÀ§
    Ã˸ŠÀÛ¿ëÀ» ³ªÅ¸³»´Â ¹°ÁúÀÇ Á᫐ ºÎÀ§.
  • catalytic reaction
    Ã˸йÝÀÀ
    Ã˸ŠÀÛ¿ë¿¡ ÀÇÇØ¼­ È­Çй°ÁúÀÇ ÀÛ¿ëÀ¸·Î ÀϾ´Â Çö»ó.
  • biomedical model
    »ýÀÇÇÐÀû ¸ðµ¨
  • biopsychosocial model
    »ý¹° »çȸ ½É¸® ¸ðÇü
  • casting model
    ÁÖÁ¶ ¸ðÇü
    µ¿ÀǾî=refractoryc cast. ³³ÇüÀÌ ¸Å¸ôÁ¦¿¡ ÀÇÇØ ¸Å¸ôµÇ¾î ÀÖ´ø ºÎºÐÀ¸·Î ¸Å¸ôÁ¦¿¡ ÀÇÇØ Çü¼ºµÈ °ÍÀ¸·Î ÁÖÁ¶ ½Ã ¿ëÀ¶µÈ ±Ý¼ÓÀÌ Èê·¯ µé¾î°¥ ¼ö ÀÖ´Â ºó °ø°£À» ¸»ÇÑ´Ù.
  • computer simulation model
    ¸ðÀÇ ÄÄÇ»ÅÍ ¸ðÇü
  • conceptual model
    °³³äÀû ¸ðÇü
  • deletion model
    °á½Ç ¸ðµ¨
    µ¹¿¬º¯ÀÌÀÇ ÇϳªÀ̸ç À¯Àü ¹°ÁúÀÇ ÀϺκÐÀÌ °á¿©µÇ¾î ÀÖ´Â °Í. ¸é¿ª À¯ÀüÇп¡¼­´Â ¸é¿ª ±Û·ÎºÎ¸°ÀÇ H¼â À¯ÀüÀÚ±ºÀ» ÆÇµ¶ÇÏ´Â ±â±¸·Î¼­ÀÇ ´ë¸³ À¯ÀüÀÚ °á½Ç ¸ðµ¨ÀÌ À¯¸íÇÏ´Ù.
  • in the ear model
    ±Í¼ÓÇü
  • integrating conceptual model
    ÅëÇÕ °³³ä ¸ðÇü
  • model
    ¸ðµ¨, º»º¸±â, ¸ðÇü, Ç¥ÁØÇü
    Áø´ÜÇÐ ¶Ç´Â ÇØºÎÇÐ ¿¬±¸¿ëÀÇ ¸ðÇü°ú °°ÀÌ ´Ù¸¥ ¹°°ÇÀ» Ç¥ÇöÇÏ´Â °Í Ä¡°úÇп¡¼­ÀÇ ÁÖÇü Ç¥º».
  • model base
    ¸ðÇü Àú¸é
    ¸ðÇüÀÇ ¹Ø¸é.
  • model mounting
    ¸ðÇü ºÎÂø
    ÀÛ¾÷ ¸ðÇü°ú ´ëÇÕ Ä¡¿­ ¸ðÇüÀ» ±³Çձ⿡ ºÎÂø½ÃŰ´Â °úÁ¤.
  • model population
    ¸ðÇü Àα¸
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
catalytic model <epidemiology> A (rather misleading name for a) type of compartmental model in which the force of infection is treated as a parameter to be estimated.
(05 Dec 1998)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
antibodies, catalytic Antibodies that can catalyze a wide variety of chemical reactions. They are characterised by high substrate specificity and share many mechanistic features with enzymes.
(12 Dec 1998)
catalytic Relating to or effecting catalysis.
(05 Mar 2000)
catalytic antibody <chemistry> Antibody raised against a transition state analogue (e.g. A phosphate analogue of a carboxylic acid ester transition state) that can then catalyse the analogous chemical reaction, though not as effectively as a true enzyme.
(16 Mar 1998)
catalytic centre See: active centre.
(05 Mar 2000)
catalytic site <chemistry> The site on an enzyme where the substrate or substrates (the reactants of a chemical or biochemical reaction) attach in order to convert to the product or products of the reaction, at a much higher speed than the substrate would need to convert to the product alone.
(16 Mar 1998)
RNA, catalytic RNA which contains an intron sequence that has an enzyme-like catalytic activity. This intron sequence has been shown to fold up to form a complex surface that can function like an enzyme in reactions with other RNA molecules and thus synthesise new molecules even in the absence of protein.
(12 Dec 1998)
Adair-Koshland-Nemethy-Filmer model <biochemistry, chemistry> A model to explain the allosteric form of cooperativity; in this model, in the absence of ligands, the protein exists in only one conformation; upon binding, the ligand induces a conformational change that may be transmitted to other subunits.
Synonym: Adair-Koshland-Nemethy-Filmer model, induced fit model.
(05 Mar 2000)
additive model A model in which the combined effect of several factors is the sum of the effects that would be produced by each of the factors in the absence of the others.
(05 Mar 2000)
age-structured model <epidemiology> A mathematical model which take into consideration the division of the host population into different age classes. Such models can used to consider the consequences of such factors as age-dependent infection, morbidity or mortality rates or of age-specific vaccination schedules.
(05 Dec 1998)
animal model Study in a population of laboratory animals that uses conditions of animals analogous to conditions of humans to simulate processes comparable to those that occur in human populations.
(05 Mar 2000)
Bingham model A model representing the flow behaviour of a Bingham plastic, in the idealised case.
(05 Mar 2000)
biomedical model A conceptual model of illness that excludes psychological and social factors and includes only biological factors in an attempt to understand a person's medical illness or disorder.
(05 Mar 2000)
biopsychosocial model A conceptual model that assumes that psychological and social factors must also be included along with the biological in understanding a person's medical illness or disorder.
(05 Mar 2000)
genetic model A formalised conjecture about the behaviour of a heritable structure in which the component terms are intended to have literal interpretation as standard structures of empirical genetics.
(05 Mar 2000)
mathematical model <epidemiology> A formal framework to convey ideas about the components of a host-parasite interaction. Construction requires three major types of information: (a) a clear understanding of the interaction within the individual host between the infectious agent and the host, (b) the mode and rate of transmission between individuals, and (c) host population characteristics such as demography and behaviour.
Mathematical models can aid exploration of the behaviour of the system under various conditions from which to determine the dominant factors generating observed patterns and phenomena. They also aid data collection and interpretation and parameter estimation, and provide tools for identifying possible approaches to control and for assessing the potential impact of different intervention measures.
(05 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • catalytic
    Ã˸Å(ÀÛ¿ë)ÀÇ
  • catalytic converter
    Ã˸ŠÄÁ¹öÅÍ(ÀÚµ¿Â÷ ¹è±â °¡½ºÀÇ À¯ÇØ ¼ººÐÀ» ¹«ÇØÈ­ÇÏ´Â ÀåÄ¡)
  • catalytic cracker
    (¼®À¯ÀÇ) Á¢ÃË ºÐÇØ±â
  • model
    ¿øÇü
  • Model T
    ¹ß´Þ ÃʱâÀÇ;±¸½ÄÀÇ
  • computer model
    ÄÄÇ»ÅÍ ¸ðµ¨(½Ã¹Ä·¹ÀÌ¼Ç µî¿¡¼­ ½Ã½ºÅÛÀ̳ª ÇÁ·ÎÁ§Æ®ÀÇ ³»¿ë µ¿ÀÛÀ» ÇÁ·Î±×·¥È­ÇÑ °Í)
  • economic model
    (°æ)°æÁ¦ ¸ðµ¨
  • fashion model
    ÆÐ¼Ç ¸ðµ¨
  • floor model
    (Ź»óÇü¿¡ ´ëÇÏ¿©) ¸¶·çÇü;ÄܼÖÇü;(»óÁ¡ÀÇ) Àü½Ãǰ (±â±¸ µî)
  • macroeconomic model
    °Å½ÃÀû °æÁ¦ ¸ðµ¨
  • model
    ¸ðÇü;¿øÇü;º»;¼³°èµµ;¸ðµ¨;¸¶³×Ų;¸ð¹ü;¸ð¹üÀûÀÎ;¸ðÇüÀÇ;¸ð¾çÀ» ¸¶µé´Ù(Á¡Åä µûÀ§¸¦ ¾î¶² ÇüÀ¸·Î)¶ß´Ù;¼³°èÇÏ´Ù;...À» º»¶ß´Ù;model school ½Ã¹ý Çб³)
  • model builder
    °æÁ¦ ¸ðµ¨ÀÇ ÀÛ¼ºÀÚ
  • model building
    ¸ðµ¨ ±¸¼º
  • model(l)er
    ¸ðÇü(¼Ò»ó)À» ¸¸µå´Â »ç¶÷
  • role model
    ¿ªÇÒ ¸ðµ¨
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á